Abstract
Abstract: Kidney transplant patients have a high case fatality rate following severe acute respiratory syndrome 2 (SARS-CoV-2) infection. In addition, the vaccine immune response is lower and less durable, which makes them more susceptible to severe forms, even when vaccinated. Evidence suggests that in addition to advanced age and the high prevalence of comorbidities often associated with worse prognosis, such as diabetes, obesity, and cardiovascular disease, prolonged immunosuppression exerts an independent effect on outcomes. In fact, the cellular and humoral adaptive immune response, which is inhibited by immunosuppression, is a key step in resolving SARS-CoV-2 infection. On the other hand, lymphocyte inhibition could modulate the aberrant production of proinflammatory cytokines that result in severe lung impairment, mitigating the severity of the condition. In addition, some immunosuppressive drugs have antiviral properties, potentially applicable to coronavirus. This narrative review aimed to discuss the available evidence on the impact of immunosuppressive drugs on COVID-19 outcomes in kidney transplant recipients
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
